Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada

Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20561333

DOI
10.1111/j.1524-4733.2010.00737.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Antibodies, Monoclonal, Murine-Derived /administration & dosage /economics; Antineoplastic Combined Chemotherapy Protocols /administration & dosage /economics; British Columbia; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide /administration & dosage /economics; Doxorubicin /administration & dosage /economics; Humans; Lymphoma, Large B-Cell, Diffuse /drug therapy /economics; Middle Aged; Outcome and Process Assessment (Health Care); Prednisone /administration & dosage /economics; Quality-Adjusted Life Years; Rituximab; Survival Analysis; Vincristine /administration & dosage /economics

AccessionNumber
22010001706

Date bibliographic record published
05/01/2011